Goldman Sachs Group Inc Astrazeneca PLC Call Options Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2025 Aug 14, 2025	SELL	$64.87 - $75.0 $116 Million - $134 Million	-1,787,300 Reduced 95.97%	75,000 $5.24 Million
Q1 2025 May 16, 2025	BUY	$65.37 - $77.96 $122 Million - $145 Million	1,862,300 New	1,862,300 $137 Million
Q3 2024 Nov 14, 2024	BUY	$76.67 - $87.62 $5.75 Million - $6.57 Million	75,000 New	75,000 $5.84 Million
Q1 2024 May 15, 2024	BUY	$61.03 - $69.57 $1.53 Million - $1.74 Million	25,000 New	25,000 $1.69 Million
Q3 2022 May 14, 2024	BUY	$53.02 - $135.75 $3.94 Million - $10.1 Million	74,300 New	74,300 $4.08 Million
Q3 2022 Nov 10, 2022	BUY	$53.02 - $135.75 $3.94 Million - $10.1 Million	74,300 New	74,300 $4.07 Million
Q4 2021 Feb 14, 2022	BUY	$54.02 - $63.83 $2.79 Million - $3.29 Million	51,600 New	51,600 $3.01 Million

1,421

498M

7.11M

2.57M

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $260B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.